Breast cancer (BRCA) is a highly heterogeneous systemic disease. It is ranked first globally in the incidence of new cancer cases and has emerged as the primary cause of cancer-related death among females. Among the distinct subtypes of BRCA, triple-positive breast cancer (TPBC) has been associated with increased metastasis and invasiveness, exhibiting greater resistance to endocrine therapy involving trastuzumab. It is now understood that invasion, metastasis, and treatment resistance associated with BRCA progression are not exclusively due to breast tumor cells but are from the intricate interplay between BRCA and its tumor microenvironment (TME). Accordingly, understanding the pathogenesis and evolution of the TPBC microenvironment demands a comprehensive approach. Moreover, addressing BRCA treatment necessitates a holistic consideration of the TME, bearing significant implications for identifying novel targets for anticancer interventions. This review expounds on the relationship between critical cellular components and factors in the TPBC microenvironment and the inception, advancement, and therapeutic resistance of breast cancer to provide perspectives on the latest research on TPBC.
乳腺癌是一种高度异质性的全身性疾病，其新发病例数量位居全球首位，已成为女性癌症相关死亡的主要原因。在乳腺癌的不同亚型中，三阳性乳腺癌与更高的转移性和侵袭性相关，对包含曲妥珠单抗在内的内分泌治疗表现出更强的耐药性。目前已知，与乳腺癌进展相关的侵袭、转移和治疗耐药性并非仅源于乳腺肿瘤细胞，而是源于乳腺癌与其肿瘤微环境之间复杂的相互作用。因此，理解三阳性乳腺癌微环境的发病机制和演变需要采取全面的方法。此外，乳腺癌的治疗也需要整体考虑肿瘤微环境，这对于发现抗癌干预的新靶点具有重要意义。本综述阐述了TPBC微环境中关键细胞成分和因子与乳腺癌的发生、进展及治疗耐药性之间的关系，以提供关于三阳性乳腺癌最新研究的视角。
肿瘤(癌症)患者之家